ArcherDX's FusionPlex Blood Cancer Panels

ArcherDX has launched the Archer FusionPlex Blood Cancer panels, three new targeted next-generation sequencing assays to capture and identify known and novel gene fusions, point mutations, and relative expression levels in myeloid and lymphoid origin malignancies. The panels utilize Archer's proprietary Anchored Multiplex PCR to detect known and novel fusions from RNA, and it also tags each input fragment with a barcode for molecular quantification for expression level detection and added confidence in mutation detection. Each new panel interrogate 80-90 genes, simultaneously detecting fusions, critical point mutations, and expression levels when analyzed using the Archer Analysis bioinformatics platform, the company said.